Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells.
Yanira ZeynGregory HarmsIngrid TubbeEvelyn MontermannNadine RöhrigMaike HartmannStephan GrabbeMatthias BrosPublished in: Cancers (2022)
Systemic administration of Fscn1 inhibitors for tumor therapy may also modulate DC-induced antitumor immune responses.